Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Biocompatible Peptide-Coated Ultrasmall Superparamagnetic Iron Oxide Nanoparticles for In Vivo Contrast-Enhanced Magnetic Resonance Imaging.

Chee HL, Gan CRR, Ng M, Low L, Fernig DG, Bhakoo KK, Paramelle D.

ACS Nano. 2018 Jul 24;12(7):6480-6491. doi: 10.1021/acsnano.7b07572. Epub 2018 Jul 11.

PMID:
29979569
2.

New tools for carbohydrate sulfation analysis: heparan sulfate 2-O-sulfotransferase (HS2ST) is a target for small-molecule protein kinase inhibitors.

Byrne DP, Li Y, Ramakrishnan K, Barsukov IL, Yates EA, Eyers CE, Papy-Garcia D, Chantepie S, Pagadala V, Liu J, Wells C, Drewry DH, Zuercher WJ, Berry NG, Fernig DG, Eyers PA.

Biochem J. 2018 Aug 14;475(15):2417-2433. doi: 10.1042/BCJ20180265.

3.

New tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors.

Byrne DP, Li Y, Ngamlert P, Ramakrishnan K, Eyers CE, Wells C, Drewry DH, Zuercher WJ, Berry NG, Fernig DG, Eyers PA.

Biochem J. 2018 Aug 14;475(15):2435-2455. doi: 10.1042/BCJ20180266.

4.

Highly efficient production of functional recombinant human fibroblast growth factor 22 in E. coli and its protective effects on H2O2-lesioned L02 cells.

Yang H, Tian H, Cheng J, Zheng J, Wang D, Sun C, Fernig D, Chen T, Gong W, Wang S, Li X, Jiang C.

Protein Expr Purif. 2018 Dec;152:114-121. doi: 10.1016/j.pep.2018.04.002. Epub 2018 Apr 5.

PMID:
29627393
5.

Functional examination of novel kisspeptin phosphinic peptides.

Zhang X, Matziari M, Xie Y, Fernig D, Rong R, Meng J, Lu ZL.

PLoS One. 2018 Apr 3;13(4):e0195089. doi: 10.1371/journal.pone.0195089. eCollection 2018.

6.

Expression and purification of an FGF9 fusion protein in E. coli, and the effects of the FGF9 subfamily on human hepatocellular carcinoma cell proliferation and migration.

Wang S, Lin H, Zhao T, Huang S, Fernig DG, Xu N, Wu F, Zhou M, Jiang C, Tian H.

Appl Microbiol Biotechnol. 2017 Nov;101(21):7823-7835. doi: 10.1007/s00253-017-8468-1. Epub 2017 Sep 18.

PMID:
28921304
7.

Differential sub-nuclear distribution of hypoxia-inducible factors (HIF)-1 and -2 alpha impacts on their stability and mobility.

Taylor SE, Bagnall J, Mason D, Levy R, Fernig DG, See V.

Open Biol. 2016 Sep;6(9). pii: 160195.

8.

Specific Internalisation of Gold Nanoparticles into Engineered Porous Protein Cages via Affinity Binding.

Paramelle D, Peng T, Free P, Fernig DG, Lim S, Tomczak N.

PLoS One. 2016 Sep 13;11(9):e0162848. doi: 10.1371/journal.pone.0162848. eCollection 2016.

9.

High colloidal stability of gold nanorods coated with a peptide-ethylene glycol: Analysis by cyanide-mediated etching and nanoparticle tracking analysis.

Free P, Conger G, Siji W, Zhang JB, Fernig DG.

Colloids Surf B Biointerfaces. 2016 Oct 1;146:871-8. doi: 10.1016/j.colsurfb.2016.07.006. Epub 2016 Jul 5.

PMID:
27455407
10.

Heparin binding preference and structures in the fibroblast growth factor family parallel their evolutionary diversification.

Li Y, Sun C, Yates EA, Jiang C, Wilkinson MC, Fernig DG.

Open Biol. 2016 Mar;6(3). pii: 150275. doi: 10.1098/rsob.150275.

11.

Selectivity in glycosaminoglycan binding dictates the distribution and diffusion of fibroblast growth factors in the pericellular matrix.

Sun C, Marcello M, Li Y, Mason D, Lévy R, Fernig DG.

Open Biol. 2016 Mar;6(3). pii: 150277. doi: 10.1098/rsob.150277.

12.

In silico analyses of heparin binding proteins expression in human periodontal tissues.

Lackey B, Nunes QM, Higham SM, Fernig DG, Valappil SP.

BMC Res Notes. 2016 Jan 28;9:53. doi: 10.1186/s13104-016-1857-1.

13.

Fibroblast growth factors as tissue repair and regeneration therapeutics.

Nunes QM, Li Y, Sun C, Kinnunen TK, Fernig DG.

PeerJ. 2016 Jan 12;4:e1535. doi: 10.7717/peerj.1535. eCollection 2016.

14.

High production in E. coli of biologically active recombinant human fibroblast growth factor 20 and its neuroprotective effects.

Tian H, Zhao Y, Chen N, Wu M, Gong W, Zheng J, Fernig DG, Jungbauer A, Wang D, Li X, Jiang C.

Appl Microbiol Biotechnol. 2016 Apr;100(7):3023-34. doi: 10.1007/s00253-015-7168-y. Epub 2015 Nov 25.

PMID:
26603761
15.

Photothermal raster image correlation spectroscopy of gold nanoparticles in solution and on live cells.

Nieves DJ, Li Y, Fernig DG, Lévy R.

R Soc Open Sci. 2015 Jun 17;2(6):140454. doi: 10.1098/rsos.140454. eCollection 2015 Jun.

16.

Structural determinants of heparin-transforming growth factor-β1 interactions and their effects on signaling.

Lee J, Wee S, Gunaratne J, Chua RJ, Smith RA, Ling L, Fernig DG, Swaminathan K, Nurcombe V, Cool SM.

Glycobiology. 2015 Dec;25(12):1491-504. doi: 10.1093/glycob/cwv064. Epub 2015 Aug 24.

PMID:
26306634
17.

Cytokines and growth factors cross-link heparan sulfate.

Migliorini E, Thakar D, Kühnle J, Sadir R, Dyer DP, Li Y, Sun C, Volkman BF, Handel TM, Coche-Guerente L, Fernig DG, Lortat-Jacob H, Richter RP.

Open Biol. 2015 Aug;5(8). pii: 150046. doi: 10.1098/rsob.150046.

18.

HaloTag is an effective expression and solubilisation fusion partner for a range of fibroblast growth factors.

Sun C, Li Y, Taylor SE, Mao X, Wilkinson MC, Fernig DG.

PeerJ. 2015 Jun 25;3:e1060. doi: 10.7717/peerj.1060. eCollection 2015.

19.

Targeting Cell Membrane Lipid Rafts by Stoichiometric Functionalization of Gold Nanoparticles With a Sphingolipid-Binding Domain Peptide.

Paramelle D, Nieves D, Brun B, Kraut RS, Fernig DG.

Adv Healthc Mater. 2015 Apr 22;4(6):911-7. doi: 10.1002/adhm.201400730. Epub 2015 Feb 3.

PMID:
25650337
20.

Network based meta-analysis prediction of microenvironmental relays involved in stemness of human embryonic stem cells.

Mournetas V, Nunes QM, Murray PA, Sanderson CM, Fernig DG.

PeerJ. 2014 Oct 23;2:e618. doi: 10.7717/peerj.618. eCollection 2014.

21.

Proliferation and migration activities of fibroblast growth factor-2 in endothelial cells are modulated by its direct interaction with heparin affin regulatory peptide.

Dos Santos C, Blanc C, Elahouel R, Prescott M, Carpentier G, Ori A, Courty J, Hamma-Kourbali Y, Fernig DG, Delbé J.

Biochimie. 2014 Dec;107 Pt B:350-7. doi: 10.1016/j.biochi.2014.10.002. Epub 2014 Oct 12.

PMID:
25315978
22.

Monovalent maleimide functionalization of gold nanoparticles via copper-free click chemistry.

Nieves DJ, Azmi NS, Xu R, Lévy R, Yates EA, Fernig DG.

Chem Commun (Camb). 2014 Nov 7;50(86):13157-60. doi: 10.1039/c4cc05909c.

PMID:
25227324
23.

A rapid method to estimate the concentration of citrate capped silver nanoparticles from UV-visible light spectra.

Paramelle D, Sadovoy A, Gorelik S, Free P, Hobley J, Fernig DG.

Analyst. 2014 Oct 7;139(19):4855-61. doi: 10.1039/c4an00978a.

PMID:
25096538
24.

Characterisation of the interaction of neuropilin-1 with heparin and a heparan sulfate mimetic library of heparin-derived sugars.

Uniewicz KA, Ori A, Ahmed YA, Yates EA, Fernig DG.

PeerJ. 2014 Jun 26;2:e461. doi: 10.7717/peerj.461. eCollection 2014.

25.

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.

Liptrott NJ, Kendall E, Nieves DJ, Farrell J, Rannard S, Fernig DG, Owen A.

Nanomedicine (Lond). 2014 Nov;9(16):2467-79. doi: 10.2217/nnm.14.38.

PMID:
24938615
26.

The heparin-binding protein interactome in pancreatic diseases.

Nunes QM, Mournetas V, Lane B, Sutton R, Fernig DG, Vasieva O.

Pancreatology. 2013 Nov-Dec;13(6):598-604. doi: 10.1016/j.pan.2013.08.004. Epub 2013 Aug 26.

PMID:
24280576
27.

Analysis of the fibroblast growth factor receptor (FGFR) signalling network with heparin as coreceptor: evidence for the expansion of the core FGFR signalling network.

Xu R, Rudd TR, Hughes AJ, Siligardi G, Fernig DG, Yates EA.

FEBS J. 2013 May;280(10):2260-70. doi: 10.1111/febs.12201. Epub 2013 Mar 13.

28.

Glycans: pervasive regulators of protein and cellular function.

Fernig D, Boraston AB.

Curr Opin Struct Biol. 2012 Oct;22(5):537-9. doi: 10.1016/j.sbi.2012.09.003. No abstract available.

PMID:
23083921
29.

Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity.

Xu R, Ori A, Rudd TR, Uniewicz KA, Ahmed YA, Guimond SE, Skidmore MA, Siligardi G, Yates EA, Fernig DG.

J Biol Chem. 2012 Nov 16;287(47):40061-73. doi: 10.1074/jbc.M112.398826. Epub 2012 Sep 27.

30.

Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate.

Duchesne L, Octeau V, Bearon RN, Beckett A, Prior IA, Lounis B, Fernig DG.

PLoS Biol. 2012 Jul;10(7):e1001361. doi: 10.1371/journal.pbio.1001361. Epub 2012 Jul 17.

31.

Array-based functional screening of heparin glycans.

Puvirajesinghe TM, Ahmed YA, Powell AK, Fernig DG, Guimond SE, Turnbull JE.

Chem Biol. 2012 May 25;19(5):553-8. doi: 10.1016/j.chembiol.2012.03.011.

32.

ANG-1 TIE-2 and BMPR signalling defects are not seen in the nitrofen model of pulmonary hypertension and congenital diaphragmatic hernia.

Corbett HJ, Connell MG, Fernig DG, Losty PD, Jesudason EC.

PLoS One. 2012;7(4):e35364. doi: 10.1371/journal.pone.0035364. Epub 2012 Apr 23.

33.

S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration.

Du M, Wang G, Ismail TM, Gross S, Fernig DG, Barraclough R, Rudland PS.

J Biol Chem. 2012 May 4;287(19):15330-44. doi: 10.1074/jbc.M112.349787. Epub 2012 Mar 6.

34.

Long-term tracking of cells using inorganic nanoparticles as contrast agents: are we there yet?

Taylor A, Wilson KM, Murray P, Fernig DG, Lévy R.

Chem Soc Rev. 2012 Apr 7;41(7):2707-17. doi: 10.1039/c2cs35031a. Epub 2012 Feb 24. Review.

PMID:
22362426
35.

Following protein-glycosaminoglycan polysaccharide interactions with differential scanning fluorimetry.

Uniewicz KA, Ori A, Rudd TR, Guerrini M, Wilkinson MC, Fernig DG, Yates EA.

Methods Mol Biol. 2012;836:171-82. doi: 10.1007/978-1-61779-498-8_12.

PMID:
22252635
36.

Structure and epitope distribution of heparan sulfate is disrupted in experimental lung hypoplasia: a glycobiological epigenetic cause for malformation?

Thompson SM, Connell MG, van Kuppevelt TH, Xu R, Turnbull JE, Losty PD, Fernig DG, Jesudason EC.

BMC Dev Biol. 2011 Jun 14;11:38. doi: 10.1186/1471-213X-11-38.

37.

A systems biology approach for the investigation of the heparin/heparan sulfate interactome.

Ori A, Wilkinson MC, Fernig DG.

J Biol Chem. 2011 Jun 3;286(22):19892-904. doi: 10.1074/jbc.M111.228114. Epub 2011 Mar 30.

38.

The cooperation of FGF receptor and Klotho is involved in excretory canal development and regulation of metabolic homeostasis in Caenorhabditis elegans.

Polanska UM, Edwards E, Fernig DG, Kinnunen TK.

J Biol Chem. 2011 Feb 18;286(7):5657-66. doi: 10.1074/jbc.M110.173039. Epub 2010 Dec 21.

39.

Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.

Uniewicz KA, Cross MJ, Fernig DG.

J Biol Chem. 2011 Jan 7;286(1):12-23. doi: 10.1074/jbc.M110.190801. Epub 2010 Oct 18.

40.

Bipartite design of a self-fibrillating protein copolymer with nanopatterned peptide display capabilities.

Bruning M, Kreplak L, Leopoldseder S, Müller SA, Ringler P, Duchesne L, Fernig DG, Engel A, Ucurum-Fotiadis Z, Mayans O.

Nano Lett. 2010 Nov 10;10(11):4533-7. doi: 10.1021/nl1024886. Epub 2010 Oct 18.

PMID:
20954695
41.

Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships.

Rudd TR, Uniewicz KA, Ori A, Guimond SE, Skidmore MA, Gaudesi D, Xu R, Turnbull JE, Guerrini M, Torri G, Siligardi G, Wilkinson MC, Fernig DG, Yates EA.

Org Biomol Chem. 2010 Dec 7;8(23):5390-7. doi: 10.1039/c0ob00246a. Epub 2010 Sep 3.

PMID:
20865198
42.
43.

Prevention of surface reconstruction at the Au(110)/electrolyte interface by the adsorption of cytosine.

Mansley CP, Smith CI, Bowfield A, Fernig DG, Edwards C, Weightman P.

J Chem Phys. 2010 Jun 7;132(21):214708. doi: 10.1063/1.3436715.

PMID:
20528042
44.

Differential scanning fluorimetry measurement of protein stability changes upon binding to glycosaminoglycans: a screening test for binding specificity.

Uniewicz KA, Ori A, Xu R, Ahmed Y, Wilkinson MC, Fernig DG, Yates EA.

Anal Chem. 2010 May 1;82(9):3796-802. doi: 10.1021/ac100188x.

PMID:
20353159
45.

Heparan sulfate in lung morphogenesis: The elephant in the room.

Thompson SM, Jesudason EC, Turnbull JE, Fernig DG.

Birth Defects Res C Embryo Today. 2010 Mar;90(1):32-44. doi: 10.1002/bdrc.20169. Review.

PMID:
20301217
46.

Self-association of calcium-binding protein S100A4 and metastasis.

Ismail TM, Zhang S, Fernig DG, Gross S, Martin-Fernandez ML, See V, Tozawa K, Tynan CJ, Wang G, Wilkinson MC, Rudland PS, Barraclough R.

J Biol Chem. 2010 Jan 8;285(2):914-22. doi: 10.1074/jbc.M109.010892. Epub 2009 Nov 16.

47.

Chapter 5 - Detection of antimycolic acid antibodies by liposomal biosensors.

Lemmer Y, Thanyani ST, Vrey PJ, Driver CH, Venter L, van Wyngaardt S, ten Bokum AM, Ozoemena KI, Pilcher LA, Fernig DG, Stoltz AC, Swai HS, Verschoor JA.

Methods Enzymol. 2009;464:79-104. doi: 10.1016/S0076-6879(09)64005-2.

PMID:
19903551
48.

The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids.

Rudd TR, Skidmore MA, Guimond SE, Holman J, Turnbull JE, Lauder RM, Fernig DG, Yates EA.

Thromb Haemost. 2009 Nov;102(5):874-8. doi: 10.1160/TH08-12-0797.

PMID:
19888522
49.

Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics: insights into protein binding specificities.

Thompson SM, Fernig DG, Jesudason EC, Losty PD, van de Westerlo EM, van Kuppevelt TH, Turnbull JE.

J Biol Chem. 2009 Dec 18;284(51):35621-31. doi: 10.1074/jbc.M109.009712.

50.

N-Glycosylation regulates fibroblast growth factor receptor/EGL-15 activity in Caenorhabditis elegans in vivo.

Polanska UM, Duchesne L, Harries JC, Fernig DG, Kinnunen TK.

J Biol Chem. 2009 Nov 27;284(48):33030-9. doi: 10.1074/jbc.M109.058925. Epub 2009 Oct 2.

Supplemental Content

Loading ...
Support Center